Aetna’s expansion affects how cancer claims are handled, while the article only highlights an oversold trading signal; the pieces cancel out for CVS.
The Aetna change changes how cancer claims are authorized for some Medicaid members, which can alter insurance costs and care timing for CVS. The story is mainly a trading note showing an RSI of 29.9 and recent share weakness. Those pieces point different ways for CVS, so this report does not change how I read the company today.
STE reported mixed first-quarter results and saw recent share weakness; the company update and price action conflict, leaving the outlook unchanged.
Baxter named a new CFO and its shares have fallen recently; that leadership item and weak price action do not change the company reading.
Follow CVS Health Corp (CVS) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for CVS